Cary Street Partners Asset Management LLC Bristol Myers Squibb CO Transaction History

Cary Street Partners Asset Management LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	SELL	$47.98 - $54.4 $42,462 - $48,144	-885 Reduced 17.61%	4,140 $224,000
Q4 2023 Feb 05, 2024	SELL	$48.48 - $57.85 $99,384 - $118,592	-2,050 Reduced 28.98%	5,025 $257,000
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $1.93 Million - $2.16 Million	-33,395 Reduced 82.52%	7,075 $410,000
Q2 2023 Aug 10, 2023	SELL	$63.71 - $70.74 $6,434 - $7,144	-101 Reduced 0.25%	40,470 $2.59 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $280,253 - $317,870	-4,265 Reduced 9.51%	40,571 $2.81 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $429,095 - $508,109	6,266 Added 16.25%	44,836 $3.23 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $33 - $19,594	-255 Reduced 0.66%	38,570 $2.74 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $964,466 - $1.06 Million	-13,281 Reduced 25.49%	38,825 $2.99 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $80,231 - $96,204	-1,305 Reduced 2.44%	52,106 $3.81 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $1.56 Million - $1.81 Million	-29,013 Reduced 35.2%	53,411 $3.33 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $141,652 - $165,928	2,394 Added 2.99%	82,424 $4.88 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $5.52 Million - $6.01 Million	-89,132 Reduced 52.69%	80,030 $5.35 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $559,694 - $629,491	9,432 Added 5.9%	169,162 $4.45 Million
Q4 2020 Feb 11, 2021	BUY	$57.74 - $65.43 $9.22 Million - $10.5 Million	159,730 New	159,730 $4.21 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Cary Street Partners Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Cary Street Partners Asset Management LLC with notifications on news.